Welcome to the e-CCO Library!

DOP15: Fluorescent labelled vedolizumab for real-time visualization and quantification of local drug distribution and pharmacodynamics in Inflammatory Bowel Diseases during endoscopy
Year: 2022
Source: ECCO'22
Authors: Gabriëls, R.Y.(1);Linssen, M.(1);van der Waaij, A.(1);Volkmer, P.(1);Hooghiemstra, W.(1);Kats-Ugurlu, G.(2);Robinson, D.(3);Dijkstra, G.(1);Nagengast, W.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP15: Intestinal ultrasound correlates with colonoscopy and biomarkers, and can be used in a tight monitoring approach to assess response to therapy in Crohn's disease: a multicentre prospective study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Morão, B.(1)*;Revés, J.(1);Nascimento, C.(1);Frias Gomes, C.(1);Cúrdia Gonçalves, T.(2);Freitas, M.(2);Castro, F.(2);Moreira, M.J.(2);Cotter, J.(2);Pereira, F.(3);Caldeira, A.(3);Sousa, R.(3);Coelho, R.(4);Macedo, G.(4);Macedo, C.(5);Ferreira, M.(5);Glória, L.(1);Torres, J.(1);Palmela, C.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP15: Metabolomics coupled with pathway analysis characterise metabolic changes in treatment-naive ulcerative colitis patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Diab*1, T. Hansen1, R. Goll2, E. Jensen1, T. Moritz3, J. Florholmen4, G. Forsdahl1

Created: Friday, 22 February 2019, 9:41 AM
DOP15: Metabolomics coupled with pathway analysis characterize metabolic changes in treatment-naive Ulcerative Colitis patients
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Joseph Diab
Created: Tuesday, 28 May 2019, 3:32 PM
Ulcerative colitis, Immunology, Metabolomics
Files: 1
DOP15: Transmural healing with vedolizumab in patients with active Crohn’s Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Shashi Adsul
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP16 An evaluation of the exposure–efficacy relationship for subcutaneous vedolizumab maintenance treatment of Crohn’s disease: Pharmacokinetic findings from VISIBLE 2
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Chen1, M. Rosario2, D. Polhamus3, N. Dirks3, W. Zhang4, W. Sun1, K. Kisfalvi5, B. Feagan6, W. Sandborn7, S. Vermeire8, G. D’Haens9

Created: Thursday, 30 January 2020, 10:12 AM
DOP16: Anti-integrin ⍺vβ6 autoantibodies predate Ulcerative Colitis diagnosis by up to 10 years and are associated with adverse disease-related outcomes
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Livanos, A.(1)*;Dunn, A.(2);Fischer, J.(2);Ungaro, R.C.(1);Turpin, W.(3);Lee, S.H.(3);Rui, S.(1);Del Valle, D.M.(2);Jougon, J.J.(4);Martinez-Delgado, G.(2);Riddle, M.S.(5);Murray, J.A.(6);Laird, R.M.(7);Torres, J.(8);Agrawal, M.(1);Magee, J.S.(9);Dervieux, T.(10);Gnjatic, S.(2);Sheppard, D.(11);Sands, B.E.(1);Porter, C.K.(7);Croitoru, K.(3);Petralia, F.(12);Colombel, J.F.(1);Mehandru, S.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP16: Categorizing endoscopic severity of Crohn’s Disease using the Modified Multiplier SES-CD (MM-SES-CD)
Year: 2022
Source: ECCO'22
Authors: Narula, N.(1);Pray, C.(1);Wong, E.(1);Colombel, J.F.(2);Marshall, J.(1);Daperno, M.(3);Reinisch, W.(4);Dulai, P.(5);
Created: Friday, 11 February 2022, 3:52 PM
DOP16: Endoplasmic reticulum stress in subepithelial myofibroblasts increases the TGF-β1 activity that regulates fibrosis in Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Li*1, J. Kuemmerle1

Created: Friday, 22 February 2019, 9:41 AM
DOP16: Endoplasmic reticulum stress in subepithelial myofibroblasts increases the TGF-β1 activity that regulates fibrosis in Crohn’s disease
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Chao Li
Created: Tuesday, 28 May 2019, 3:32 PM
Epigenetics, Fibrosis, Mesenchymal cell
Files: 1
DOP16: The ratio of submucosa thickness to the total bowel wall thickness can be a sonographic parameter to estimate endoscopic remission in Ulcerative Colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Miyoshi, J.(1);Ozaki, R.(1);Yonezawa, H.(1);Mori, H.(1);Kawamura, N.(1);Matsuura, M.(1);Hisamatsu, T.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP16: Transmural healing with vedolizumab in patients with active Crohn’s Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Maria Rosario
Created: Tuesday, 23 June 2020, 5:40 PM
Last Modified: Thursday, 2 July 2020, 12:10 PM by Eloise Lanaud
DOP17 Identification of biomarkers and mechanistic insight for upadacitinib in ulcerative colitis: Analysis of serum inflammatory mediators in the phase 2b U-ACHIEVE study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Vermeire1, H. Guay2, B. Verstockt3, J. Fann4, J. Cheng4, F. Hong4, W.J. Lee5, A. Lacerda6, W. Zhou6, S. Danese7

Created: Thursday, 30 January 2020, 10:12 AM
DOP17: AZD4205, a potent, GI tract-enriched, JAK1-selective inhibitor for treatment of Inflammatory Bowel Disease (IBD)
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Mei Wang
Created: Tuesday, 28 May 2019, 3:32 PM
JAK inhibitors, Immunology, Lymphocyte, T cell
Files: 1
DOP17: AZD4205, a potent, GI tract-enriched, JAK1-selective inhibitor for treatment of inflammatory bowel disease (IBD)
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Wang*1, T. John2, L. Zhang1, L. Zhu1, Y. Xu1, K. Chen1, S. Han1, J. Li1, F. Wang1, C. Deceneux3,4, A. Behren3,4, Z. Yang1

Created: Friday, 22 February 2019, 9:41 AM